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Summary 
Experimental lergic encephalomyelitis (EAE) is an autoimmune disease that can be induced 
in laboratory animals by immunization with the major myelin proteins, myelin basic protein 
(MBP) and proteolipid protein (PLP). We analyzed the role of the T cell receptor (TCR) repertoire 
in susceptibility o EAE induced by these two autoantigens. Autoreactive T cells induced after 
immunization with MBP use a limited set of TCR. In contrast, we demonstrate that T cell 
clones that recognize the encephalitogenic PLP epitope (PLP 139-151) use diverse TCR genes. 
When the TCR. repertoire is limited by introduction of a novel rearranged TCR V/~ 8.2 chain 
in transgenic SJL mice, EAE could be induced in the transgenic mice by immunization with 
the encephalitogenic epitopes of PLP, but not with the encephalitogenic epitope of MBP. Thus, 
skewing the TCR repertoire affects the susceptibility o EAE by immunization with MBP but 
not with PLP. These data demonstrate the biological consequences of the usage of a more diverse 
T cell repertoire in the development of an autoimmune disease. 
E xperimental utoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis (MS) (1), can 
be induced in laboratory animals by immunization with the 
major myelin proteins, myelin basic protein (MBP) or my- 
elin proteolipid protein (PLP) (2, 3). The EAE that results 
from immunization with MBP is mediated by T cells that 
utilize limited sets of TCR (4-6). PLP, which constitutes 
the bulk of the myelin proteins in the central nervous ystem 
(CNS), is an equally important candidate antigen for MS. 
A panel of T cell clones pecific for the encephalitogenic epi- 
tope of PLP 139-151 was recently isolated and characterized 
(7). Cloning and sequencing of the TCR genes reveals that 
diverse TCR c~/~ chains are used by these clones. We dem- 
onstrate the consequence of the diversity of TCR gene usage 
in response toPLP and MBP by analyzing the effect of skewing 
the TCR repertoire on the pathogenesis and susceptibility 
to EAE in SJL-TCR. V/3 8.2 transgenic mice. 
Materials and Methods 
Animals. Female SJL/J mice (4-8-wk-old) were from the Jack- 
son Laboratory (Bar Harbor, ME). Transgenic mice were produced 
by injecting the TcR/~ chain construct (V/~ 8.2-D/31.1-JBI.I-CB2) 
(8), derived from an OVA-specific T cell hybridoma, into the product 
of a (C57BL/6 x SJL)F: mating. The founder animal was back- 
crossed twice to SJL/J mice and the offspring were H-2 typed. 
The H-2 s/~ homozygotes were then backcrossed an additional four 
times to SJL/J mice. This strain was termed SJL transgenic and 
was maintained bybackcrosses to SJL mice. In all experiments, non- 
transgenic mice were littermates of transgenic mice. 
Antigens. Whole mouse myelin was prepared from the brains 
and spinal cords by the method of Norton and Poduslo (9). The 
MBP and PLP peptides used in the study were: MBP 89-101 
(VHFFKNIVTPRTP), MBP 17-27 (TASTMDHARH), MBP 1-11 
(ASQKR.PSQRHG), MBP 35-47 (TGILDSIGRFFSG), PLP 139- 
151 (HSLGKWLGHPDKF), PLP 178-191 (NTWTTCQSIAF- 
PSK), and PLP 103-116 (YKTTICGKGLSATV). Peptides were syn- 
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thesized inthe laboratory of Dr. Richard Laursen (Boston Univer- 
sity, Boston, MA) or by Hans Freisheim (Medical College of Ohio, 
Toledo, OH). 
Antibodies. The following antibodies were used: anti-V38.1 and 
8.2 (KJ 16-133, obtained from Phillipa Marrack and John Kappler, 
National Jewish Center of Immunology and Respiratory Medi- 
cine, Denver, CO); anti-V36 (46-6-B5, from Hans Hengartner, 
University of Zurich, Zurich, Switzerland); anti-V/~4 (KT 10.4, 
from Dr. Robert Clark, University of Connecticut, Farmington, 
CT); anti-V~11 (RR 3-15, from Dr. Ed Palmer, National Jewish 
Center of Immunology and Respiratory Medicine); and anti-CD4 
(GK 1.5, from Dr. Frank Fitch, University of Chicago, Chicago, IL). 
T Cell Clones and Hybridomas. The five T cell clones used have 
been described (7). Hybridomas were prepared (10) from each of 
the clones and were used to isolate some TCR genes. 
Cloning and Sequendng ofTCR Genes. Full-length cDNA clones 
for TCR~ from 5B6, 7A5, and 4E3 and for TCR3 from 7A5 and 
4E3 were isolated from unamplified XZap (Stratagene, La Jolla, CA) 
libraries, and the DNA sequence of multiple clones were deter- 
mined. The SPLI.1 TCRoe was identified using inverse PCR (11) 
using two Cc~ primers. The full-length cDNA clone was then iso- 
lated by using a primer specific for the predicted Vcd5 leader se- 
quence (AAATTTGAATTCATGAAGACATCCCTTCACACT- 
GTA) with 3' Cc~ (AAATTTGAATTCAACTGGACCACAGCC- 
TCA) primers. The 2E5 TCRc~ clone was identified by PCR using 
a degenerate Vc~ primer (12) and a Cc~ primer and independently 
cloned by PCR with the above Veal5 and Cc~ primers and se- 
quenced. The 2E5 and SPLI.1 TCR 3 chains were isolated by PCR 
with a V317a specific primer (ATGGGTGCAAGACTGCTCTGC- 
TGTGTAGCA) or V32 primer (ATGTGGCAGTTTTCCATT- 
CTGTGCCTCTGC), and a 3' C3 (AAATTTGAATTCTGATGT- 
TCTGTGTGACAGGT) primer. The 5B6 TCR3 clones were iso- 
lated by PCR using a degenerate V3 oligonucleotide (13) and the 
3' C3 primer; sequence ofclones from a second PCR reaction with 
V~6 and C3 primers confirmed that this was derived from a full- 
length transcript. 
In Vitro Proliferation. Mice were immunized subcutaneously with 
100/zg of PLP or MBP peptides in 0.1 ml of CFA containing 200 
/~g of heat killed Mycobacterium tuberculosis H37RA (Difco Labora- 
tories, Detroit, MI). Cells from inguinal, prescapular, nd para- 
aortic lymph nodes were dissociated and cultured at 5 x 10 s 
cells/well with peptide in DMEM (GIBCO BRL, Gaithersburg, 
MD) containing 10% FCS in 96-well plates for 72 h and then pulsed 
with 1 #Ci of [3H]thymidine for 16-18 h. Mean thymidine incor- 
poration from triplicate wells was calculated. Antibodies were used 
as culture supernatants forblocking studies. 
EAE Studies. Mice were injected subcutaneously in the flank 
with 2 mg of whole mouse myelin or 50 or 70 nmol of peptide 
and 400/~g of M. tuberculosis H37Ra (Difco) in an emulsion con- 
sisting of equal volumes of water and CFA. Each mouse was also 
injected intravenously onday 0 and days 2, 3, or 4 with 109 heat 
killed Bordetella ioertussis bacilli (Pertussis vaccine lot no 264; Mas- 
sachusetts Public Health Biological Laboratories, Boston, MA) or 
200 ng pertussis toxin (List Biological Laboratories, Inc., Camp- 
bell, CA). Clinical assessment was carried out daily as described (7). 
Brains and spinal cords were removed and fixed in 10% phosphate- 
buffered formalin, and paraffin-embedded sections were stained for 
light microscopy. Histological disease was quantified by counting 
inflammatory loci in meninges and parenchyma (7). For evaluation 
of TCR V/~ expression i the tissues, the brains and samples of 
spleen and thymus were frozen in OCT compound (Miles Labora- 
tories, Naperville, IL) and stored at - 70~ 4-6/zm-thick cryostat 
tissue sections were immunostained with undiluted anti-TCR V3 
hybridoma culture supernatants u ing avidin-biotin immuno- 
histochemical staining kits (Vector Laboratories, Inc., Burlingame, 
CA). 
Results and Discussion 
We examined TCR usage in a panel of T cell clones pecific 
for the encephalitogenic PLP epitope 139-151 (7). These PLP- 
specific T cell clones use a variety of TCR Vot, Jot and V3, 
D3, and J3 segments (Fig. 1). Two of the T cell clones (2E5 
and SPLI.1) used the same Vot15 segment in combination 
with different Jot segments, thereby creating diverse junc- 
tional regions. The Jot8 segment was used by clones SPLI.1 
and 5B6 in combination with different Vot segments. The 
V3 segments were all different, with only two of the clones 
using the same J3 segment. A conserved junctional motif 
was not observed in the CDR3 region of the TCR ot or 
chains. In the TCR ot chain, the threonine at position 2within 
the conserved GXGT motif adjacent to the predicted CDR3 
region, may be selected in that it is in four of the five se- 
quences and is present in a minority (6/47) of germline Joe 
segments (14). Thus, a wider variety of the TCR genes is 
used in response to this PLP epitope than in response to en- 
cephalitogenic MBP epitopes. TCR 3 chain diversity has also 
been observed with two other encephalitogenic PLP epitopes 
in SJL (15) and in (PL/J x SJL)F1 mice (Kuchroo, V. K., 
unpublished ata). 
The difference between the limited TCR diversity in re- 
sponse to MBP determinants and the diverse response for PLP 
epitopes could affect susceptibility oEAE induced by these 
two myelin autoantigens. One prediction would be that limi- 
tation of the TCR diversity would have a profound effect 
on the ability of MBP, but not PLP, to induce EAE. We ex- 
amined the ability of encephalitogenic MBP and PLP epi- 
topes to induce EAE in transgenic SJL mice containing a single 
rearranged TCR 3 chain transgene (8, 16). The transgene 
is expressed on >95% of peripheral T cells in the transgenic 
mice. This transgene, which is not specific for either MBP 
or PLP, was chosen because the TCR V38.2 is deleted in 
Vc( 
2E5:V~15 ]j~4 
SPL: V~15 ]j~8 
5B6:Va4 J~8 
7A5:V~13 J~27 
4E3: V~ll ]j~12 
TCR~ ]JUNCTIONAL SEOUENCE 
HITATQPEDSAIYFCAIASPGANTG.KLT]FGHGTILRVHPN 
HITATQPEOSAIYFCAIASTGGNMGYKLTIFGTGTSLLVDPN 
QKASVQESDSAVYFCAIL.VGSMGYKLTIFGTGTSLLVDPN 
KKSPAHWSOSAKYFCA L..EVSNTDKVVIFGTGTRLQVSPN 
HIROAQLEDSGTYFCA VLYQGGRA..LI FGTGTTVSVSPN 
W DB 2]] TCRB JUNCTIONAL SEOUENCE 
2E5: VI317A O1~1 ]ji]1.2 SSEEDDSALYLCASISLVRGNS.OYTIFGSGTRLLVl 
SPL: V~2 O112 3132.5 VANMSQGRTLYCTC SAVQGQD.TQYIFGPGTRLLVL 
5B6:V!36 DI~2 3132.6 SAQKNEMAVFLCAS SRGGRSSYEQY I FGPGTRLTVL 
7A5:V1310 D132 3~2.4 SVELEDSAVYLCAS SHWGVQN.TLY FGAGTRLSVL 
4E3:V~16 Dl32 .1132.5 PTALEDSAVYFCAS SFGGLQD.TQY FGPGTRLLVL 
Figure 1. Predicted amino acid sequence of V(D)J junctions of TCR 
oe and 3 chains from PLP-peptide 139-151 specific T cell clones. Boxed 
residues correspond to predicted CDR3 regions (25). The asterisk marks 
the threonine r sidue that may be selected in TCRot. Assignments to V, 
D, and J segments are based on references (14, 26, 27). Sequence data re 
available from EMBL/GenBank/DDBJ under accession umbers 
(U07653-U07662). 
1660 TCR Use and Susceptibility n Experimental Autoimmune Encephalomyelitis 
Table 1. Clinical and Histological EAE Induction in SJL Transgenic and Nontransgenic Mice 
Nontransgenic Transgenic 
Maximum Number of Maximum Number 
Clinical Mean day clinical inflammatory Clinical Mean day clinical inflammatory 
Antigen incidence of onset grade loci incidence of onset grade foci 
Mouse myelin 8/8 12.1 _+ 0.8 3.9 _+ 1.0 96 7/7 17.1 + 4.5* 2.6 _+ 1.0" 96 
PLP 139-151 4/5 13.3 _+ 2.1 3.8 _+ 0.5 46 4/5 30.0 _+ 10.5" 3.3 -+ 1.3 98 
PLP 178-191 4/5 12.3 _+ 0.9 3.3 +_ 1.5 62 4/6 14.3 _+ 1.3 2.8 _+ 1.5 70 
MBP 89-101 6/7 16.2 + 6.1 3.7 _+ 1.2 45 0/7 - - 0 
The SJL transgenic and littermate mice were immunized subcutaneously with 2 mg of whole mouse myelin or 150/~g of the individual peptides 
emulsified in CFA, and pertussis toxin as described in Materials and Methods. Mice were assessed clinically according to following criteria: 0, no 
disease; 1, tail atony; 2, hind limb weakness and/or poor righting ability; 3, hind limb paralysis; 4, hind- and fore-limb paralysis; 5, moribund. 
Mice showing clinical signs were killed at the peak of the disease and paraffin-embedded s ctions were stained with Luxol fast blue-hematoxylin 
and eosin for light microscopy. Disease induction was confirmed and quantified histologically by counting the number of inflammatory loci in the 
white matter in representative mice in each group. Animals were killed within 7-10 d of the initial appearance of clinical signs or at the peak of 
the disease. Mice that show no clinical signs were killed 40 d after immunization. 
The data are presented as mean _+ SE. (,) Significant difference (p <0.04-p <0.008) when compared with values obtained with nontransgenic litter- 
mates by Student's t test. 
SJL mice (17) and the T cell response to MBP is mediated 
by V/~8.2 in other mouse strains and in Lewis rats (4-6). 
The transgenic mice and the nontransgenic controls that 
were immunized with either mouse myelin or encephalito- 
genic PLP peptides 139-151 or 178-191 developed clinical EAE, 
although the disease occurred earlier and appeared to be more 
severe in the nontransgenic littermates (Table 1). At the peak 
of the disease, however, both groups had similar numbers 
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Figure 2. In vitro proliferative r sponse of lymph node cells from SJL 
transgenic and nontransgenic mice to the encephalitogenic PLP and MBP 
peptides. (A-F) Lymph node cells were isolated from mice immunized 
10-12 d earlier with PLP or MBP peptides in CFA and tested with pep- 
tides at the indicated concentrations. Proliferative r sponses were measured 
as described inMaterials and Methods. Data from one of the three experi- 
ments is shown. (G and/-/) Lymph node cells were isolated as for A-F, 
incubated with 100/~g of PLP 13%151, and the indicated concentrations 
of anti-TCR V/~ and anti-CD4 antibodies, and proliferation was measured. 
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Figure 3. Transgenic and nontransgenic mice were immunized with 
PLP-peptide 139-151 in CFA. Brains, spinal cords, and lymphoid tissues 
were obtained atthe peak of the disease for histopathological andimmuno- 
histochemical analysis. (A) Typical perivascular mononuclear cell infiltrate 
in a paraffin section of the spinal cord of a transgenic mouse immunized 
with PLP 139-151. Demyelination s indicated by pink staining, whereas 
intact white matter myelin is stained blue. Luxol fast blue-hematoxylin 
and eosin, x218. (B) Numerous TCR Vfl 8 + cells (arrowheads) in an acute 
EAE lesion in the brain of a Vfl8 transgenic SJLmouse. Cryostat section, 
mAb KJ 16-133 immunoperoxidase withhematoxylin. • (C) Section 
adjacent toB stained with anti-TCR Vfl4 antibody. Cryostat section anfiVfl4 
with hematoxylin, x340. 
of inflammatory lesions (Table 1). In contrast, immunization 
with the dominant encephalitogenic MBP epitope 89-101 did 
not result in EAE in the transgenic mice, whereas the non- 
transgenic control mice developed typical EAE (Table 1). These 
1662 
results show that limitation of the TCR/3 chain diversity 
to a single/3 chain gene results in loss of susceptibility to 
disease induction by the dominant MBP epitope but not by 
either of the PLP epitopes. 
The difference in susceptibility oEAE suggested that both 
PLP peptides elicited encephalitogenic T ell responses in the 
transgenic mice, but that the dominant MBP determinant 
did not. We examined in vitro proliferation of lymph node 
T cells in response to the encephalitogenic determinants of
MBP and PLP. Lymph node cells from mice immunized with 
PLP peptide proliferated in response to the immunizing PLP 
peptide, but not to other control PLP or MBP peptides. How- 
ever, the proliferative r sponses of the lymph node cells iso- 
lated from the transgenic mice were reduced by a factor of 
three to four compared with those from nontransgenic con- 
trols (Fig. 2, A-D). In contrast, little or no proliferative r - 
sponse was detected in lymph node cells isolated from trans- 
genic mice immunized with MBP 89-101, despite the strong 
proliferative r sponse observed in lymph node cells from non- 
transgenic littermates (Fig. 2, E and F). Thus, the transgenic 
mice appear to be unable to develop aproliferative T cell re- 
sponse to the dominant MBP determinant 89-101. TCR-/3 
transgenic mice are unable to recognize some p ptides (18) 
probably because of limitation in the available TCR reper- 
toire. This may account for the lack of T cell response and 
the lack of disease in transgenic mice immunized with MBP 
89-101. 
Non-V/38 § T cells, which constitute <5% of the total T 
cell pool in the transgenic mice (8), could be responsible for 
the induction of EAE with the encephalitogenic PLP deter- 
minants. The proliferative responses of lymph node cells from 
transgenic and nontransgenic littermate mice immunized with 
PIP 139-151 were examined in the presence of anti-V/38 (KJ16) 
mAb. The anti-V/38 mAb blocked the PLP 139-151 specific 
proliferative response of lymph node cells from transgenic 
mice, but not the response of lymph node cells from non- 
transgenic mice. Antibodies to other TCR V/3 chains (V/3 
4, 6, and 11) did not inhibit the proliferation of transgenic 
lymph node cells in response to PLP 139-151 (Fig. 2, G and 
H). By immunohistochemistry, he vast majority of the T 
cells in the lymphoid tissue from the transgenic mice expressed 
V/3 8 (~95-99%) with rare, scattered cells expressing some 
of the other TCR V/3 (V/34 and V/36). In contrast, lym- 
phoid tissues from the nontransgenic littermates were totally 
devoid of VflS-bearing cells and expressed larger numbers 
of TCR V/34, V/36, and other TCR V/3s (data not shown). 
Immunocytochemical staining of the inflammatory lesions 
in the CNS of the transgenic mice demonstrated the pres- 
ence of V/38 + cells and virtually no other V/3-bearing T cells 
(Fig. 3, B and C). Consistent with previous results (19), the 
T cells constituted ~30% of the total inflammatory cell popu- 
lation in the EAE lesions, which corresponded to the number 
of V/38 + cells detected in the EAE lesions of the transgenic 
mice (Fig. 3 B). In contrast, in the nontransgenic control 
mice (which lack V38), accumulation f T cells expressing 
various TCR V/3s (V/3 2, 4, 6, 7, and 14) was seen in the 
infiltrates, but no TCR V/38-bearing cells were detected ( ata 
not shown). 
TCR Use and Susceptibility n Experimental Autoimmune Encephalomyelitis 
Analyses of TCK usage by MBP-specific T cell clones in 
mice, rats, and humans have suggested a restricted TCK Vl3 
usage (4-6, 20, 21). Both mouse and rat MBP-specific en- 
cephalitogenic T cell clones use the same Vl3 gene segment 
(V138.2). The "V-region disease hypothesis" (22) proposed 
that TCK V138.2 in association with a specific TCK Vc~ may 
recognize a ligand in the CNS and induce EAE. SJL mice 
do not express aV138.2 gene segment (17), but introduction 
of a V~8.2 transgene into the SJL T cell repertoire provided 
us with a unique opportunity to test the role of this V gene 
in the induction of EAE. Overexpression f a V138.2 trans- 
gene in SJL mice did not permit an immune response to MBP 
89-101 (Fig. 2 F) or development of EAE (Table 1). The T 
cell response to MBP 89-101 is largely mediated by VB17a- 
and V134-bearing cells (23, 24). Limitation of the TCK 13 
chain repertoire to a single rearranged 13chain does not permit 
development of an immune response to this encephalitogenic 
MBP epitope. In contrast, the severe limitation on TCK IS 
chain diversity does not prevent a T cell response to en- 
cephalitogenic PLP epitopes or the induction of EAE in a 
susceptible mouse strain. T cells using the novel rearranged 
TCK/3 chain are therefore able to recognize the encephalito- 
genic PLP epitopes and induce EAE. Although the autoan- 
tigen(s) involved in MS has not been identified, PLP could 
be involved in pathogenesis of MS. Our data would suggest 
that T cell responses to PLP epitopes may differ from those 
to MBP epitopes and that this finding should be considered 
in the design of TCK-based therapies for MS. 
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